Status:
COMPLETED
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
Brief Summary
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval. * Unexpected adverse events...
Eligibility Criteria
Inclusion
- Among the patients with idiopathic Parkinson's disease, from those receiving MIRAPEX Tablets first after a contract of the study to the requested number of cases will be consecutively enrolled without skipping
Exclusion
- Following patients are contraindicated.
- Patients who are hypersensitive to MIRAPEX or its ingredients
- Refer to the insert paper for other contraindication.
- Following patients should be carefully administered.
- Patient with renal impairment
- Refer to the insert paper for other precaution.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1449 Patients enrolled
Trial Details
Trial ID
NCT02248168
Start Date
March 1 2002
Last Update
September 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.